The right to offer patients a choice to use the cheap, effective drug bevacizumab (Avastin) to treat wet age-related macular degeneration, has been a long time coming. In September 2018 – after just under a decade of being thwarted by judicial review and lobby – the NHS finally won the right to do so. It’s a situation Deborah has been investigating for many years.

Write A Comment